A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)
The purpose of this research study is to evaluate the safety and effectiveness of a new oral
 antibiotic called SMT19969 in treating C. difficile Infection (CDI).
Inclusion Criteria:

 -  Informed consent

 -  Clinical diagnosis of CDAD plus laboratory diagnostic test

 -  No more than 24 hrs antimicrobial treatment for current CDAD episode

 -  No more than 3 episodes of CDAD in prior 12 months

 -  No previous episode of CDAD within 30 days of study enrollment

 -  Female subjects of childbearing potential must use adequate contraception

 Exclusion Criteria:

 -  Life-threatening or fulminant colitis

 -  Concurrent use of antibiotics or any other treatments for CDAD

 -  History of inflammatory bowel disease (ulcerative colitis, Crohn's disease)

 -  Participation in other Clinical research studies within one month of screening